<DOC>
	<DOCNO>NCT00577889</DOCNO>
	<brief_summary>This randomized phase II trial study three different schedule gemcitabine hydrochloride tanespimycin see well work treat patient stage IV pancreatic cancer . Drugs use chemotherapy , gemcitabine hydrochloride tanespimycin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell</brief_summary>
	<brief_title>Gemcitabine Hydrochloride Tanespimycin Treating Patients With Stage IV Pancreatic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess effect gemcitabine hydrochloride tanespimycin ( 17-AAG ) 6-month survival rate patient stage IV pancreatic adenocarcinoma . SECONDARY OBJECTIVES : I . To determine overall survival patient . II . To determine time disease progression ( TTP ) patient . III . To determine confirm response rate duration response patient . IV . To determine time treatment failure patient . V. To determine adverse event patient . TERTIARY OBJECTIVES : I . To determine effect treatment molecular target , CDK4 , akt , phospho-akt , Hsp90 , Hsp70 , CHK1 , correlate clinical endpoint , include survival 6 month , TTP , response rate , overall survival . II . To determine effect gemcitabine hydrochloride metabolize enzyme genotype toxicity , clinical outcome . OUTLINE : This multicenter study . Patients stratify accord Eastern Cooperative Oncology Group ( ECOG ) performance status ( 0 , 1 , 2 ) . Patients randomize 1 3 treatment arm . ARM I : Patients receive gemcitabine hydrochloride intravenously ( IV ) 30 minute day 1 8 tanespimycin IV 1 hour day 9 course one . ARM II : Patients receive gemcitabine hydrochloride IV 30 minute day 1 8 tanespimycin IV 1 hour day 2 9 course one . ARM III : Patients receive gemcitabine hydrochloride IV 30 minute day 8 tanespimycin IV 1 hour day 1 9 course one . Beginning course two ( subsequent course ) , patient receive gemcitabine hydrochloride IV 30 minute day 1 8 tanespimycin IV 1 hour day 2 9 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Blood sample collect baseline periodically treatment pharmacogenetic study . Tumor tissue sample available also collect laboratory study . Samples analyze number circulate tumor cell , level intracellular target ( e.g. , CDK4 , akt , phospho-akt , Hsp90 , Hsp70 , CHK1 ) , single nucleotide DNA polymorphism , Vav1 expression . Samples analyze reverse transcriptase-polymerase chain reaction , immunofluorescence , immunohistochemistry . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically cytologically confirm pancreatic adenocarcinoma Clinical stage IV disease No known brain metastasis ECOG performance status 02 Life expectancy ≥ 12 week Absolute Neutrophil Count ( ANC ) ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin normal Aspartate aminotransferase ( AST ) ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN ( 5 time ULN liver metastasis present ) Creatinine normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Ejection fraction &gt; 40 % echocardiogram Patients receive prior anthracyclines must normal ejection fraction echocardiogram Corrected QT interval ( QTc ) &lt; 500 msec Pulse oximetry &gt; 88 % room air rest gentle exercise ( accord Group Medicare Guidelines ) No history allergic reaction attribute compound similar chemical biologic composition tanespimycin ( 17AAG ) gemcitabine hydrochloride No known allergy egg No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement No active ischemic heart disease within past 12 month No history uncontrolled dysrhythmias No congenital long QT syndrome No leave bundle branch block No significant cardiac disease , include follow : New York Heart Association class III IV heart failure Myocardial infarction within past year Poorly control angina Uncontrolled dysrhythmias History serious ventricular arrhythmia ( ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) No clinically significant interstitial lung disease No symptomatic pulmonary disease require medication , include follow : Dyspnea Dyspnea exertion Paroxysmal nocturnal dyspnea Significant pulmonary disease require oxygen* , include chronic obstructive/restrictive pulmonary disease No pulmonary cardiac symptom ≥ grade 2 No history cardiac pulmonary toxicity receive anthracyclines ( e.g. , doxorubicin hydrochloride , daunorubicin hydrochloride , mitoxantrone hydrochloride , bleomycin , vincristine ) No prior chemotherapy metastatic disease No prior radiotherapy chest No prior radiotherapy potentially include heart field ( e.g. , mantle radiotherapy ) More 3 month since prior adjuvant chemotherapy chemotherapy locally advance disease More 3 week since prior radiotherapy No concurrent medication prolong may prolong QTc No concurrent antiarrhythmic drug No concurrent prophylactic colonystimulating factor No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>